Skip to main content
Download PDF

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis

Arthritis Research & Therapy volume 24, Article number: 160 (2022) Cite this article

Abstract

Objective

To assess markers of neutrophil activation such as calprotectin and N-formyl methionine (fMET) in anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) and large-vessel vasculitis (LVV).

Methods

Levels of fMET, and calprotectin, were measured in the plasma of healthy controls (n=30) and patients with AAV (granulomatosis with polyangiitis (GPA, n=123), microscopic polyangiitis (MPA, n=61)), and LVV (Takayasu’s arteritis (TAK, n=58), giant cell arteritis (GCA, n=68)), at times of remission or flare. Disease activity was assessed by physician global assessment. In vitro neutrophil activation assays were performed in the presence or absence of formyl peptide receptor 1 (FPR1) inhibitor cyclosporine H.

Results

Levels of calprotectin, and fMET were elevated in patients with vasculitis as compared to healthy individuals. Levels of fMET correlated with markers of systemic inflammation: C-reactive protein (r=0.82, p<0.0001), and erythrocyte sedimentation rate (r=0.235, p<0.0001). The neutrophil activation marker, calprotectin was not associated with disease activity. Circulating levels of fMET were associated with neutrophil activation (p<0.01) and were able to induce de novo neutrophil activation via FPR1-mediated signaling.

Conclusion

Circulating fMET appears to propagate neutrophil activation in AAV and LVV. Inhibition of fMET-mediated FPR1 signaling could be a novel therapeutic intervention for systemic vasculitides.

Introduction

Neutrophils are important mediators of the innate immune system and play a significant role in host defense against pathogenic microorganisms [1], via their recruitment at sites of tissue infection where they phagocytize pathogens, produce reactive oxygen species (ROS), and release neutrophil extracellular traps (NETs) [2]. NETs are webs of extruded chromatin, citrullinated histones, and granular components, including proteinase 3 (PR3), neutrophil elastase (NE), calprotectin (also known as S100A8/A9 or myeloid-related protein 8/14 (MRP8/14)), and myeloperoxidase (MPO) [3, 4]. NETs contribute to the pathogenesis of many autoimmune diseases [5,6,7], including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) [8], a disease of small blood vessels characterized by the presence of circulating ANCA [9]. AAV includes three different subtypes, namely granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [10].

In AAV, neutrophil activation by ANCA depends on priming by inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), lipopolysaccharide (LPS), or complement factor 5a (C5a). These stimuli lead to externalization of the antigens MPO, and PR3 to the neutrophil cell surface where ANCA can bind to them. Upon binding, the Fc part of the autoantibody crosslinks FcγRs, resulting in profound neutrophil activation, NET formation, and inflammatory damage to the endothelium [11,12,13]. However, the role of neutrophil activation and NET formation in large-vessel vasculitis (LVV), which includes Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), characterized by vascular inflammation and damage of the aorta and/or major branch arteries [14, 15], is still unknown.

NETs release mitochondrial components that signal through DNA sensing TLR9 as well as the cGAS-STING pathway [16]. Mitochondrial-derived N-formyl methionine peptides (fMET) are known potent neutrophil chemoattractants [17, 18]. fMET acts primarily through a highly expressed G-protein coupled receptor, formyl peptide receptor 1 (FPR1), inducing neutrophil chemotaxis, degranulation, and reactive oxygen species (ROS) generation [19,20,21,22]. Blockade of the neutrophil receptor FPR1 with the selective antagonist cyclosporine H (CsH) impairs neutrophil chemotaxis towards necrotic cells [23].

Although fMET plays a role in the pathogenesis of many inflammatory diseases such as inflammatory bowel diseases [24, 25], and rheumatoid arthritis (RA) contributing to neutrophil-mediated inflammation and disease progression [26], the role of fMET in the pathogenesis of vasculitides remains unclear.

In the current study, we first investigated levels of the neutrophil activation marker calprotectin, as well as levels of fMET, in a large cohort of patients with AAV and LVV. Secondly, we assessed whether levels of neutrophil activation were associated with disease activity and inflammatory markers. Finally, we investigated whether fMET/FPR1-mediated signaling can drive neutrophil activation in patients with vasculitis.

Materials and methods

Patient characteristics

Plasma samples from patients with GPA (123 patients in remission, 73 paired samples with flare), MPA (61 patients in remission, 11 paired samples with flare), TAK (58 patients in remission, 8 paired samples with flare), and GCA (68 patients in remission, 18 paired samples with flare) who had been enrolled in the Vasculitis Clinical Research Consortium (VCRC) were analyzed in this study. Demographic data, including disease subgroups, gender, age at diagnosis, and disease duration for the study populations in remission and active disease were also recorded (Tables 1 and 2, respectively). For the GPA and MPA cohorts, the prevalence of anti-MPO and anti-PR3 antibodies is also detailed.

Table 1 Demographic characteristics of study populations in remission
Full size table
Table 2 Demographic characteristics of study populations in active disease
Full size table

Disease activity was assessed using physician global assessment (PGA) in all patients with vasculitis. PGA correlates well with the Birmingham Vasculitis Activity Score (BVAS) [27]. For all patients, laboratory data such as creatinine, and markers of systemic inflammation (CRP and ESR) were collected. Additionally, for patients with GCA, overlap with polymyalgia rheumatica (PMR) was recorded.

Plasma from healthy individuals (HC, n=30) were recruited through the University of Washington. The study was approved by the appropriate local institutional review boards at the University of Washington, Seattle, WA, (#3100), and informed consent was obtained from all participants in accordance with the Helsinki Declaration.

ELISA assays

Plasma levels of human N-formyl methionine (My BioSource Inc., San Diego, CA, USA) and calprotectin (R&D Systems, Minneapolis MN, USA)) were measured by ELISA following the manufacturers’ instructions. Absorbance was measured by a plate reader at 450 nm (Synergy 2, BioTek).

Neutrophil isolation

Heparinized blood from healthy individuals was layered on Polymorphprep (Axis-Shield, Dundee, UK) density gradient, according to the manufacturer’s instructions, or as described previously [28,29,30]. Red blood cells were lysed using RBC lysis buffer (BioLegend, San Diego, CA, USA). Neutrophils were re-suspended in serum-free RPMI-1640 medium (Life Technologies, Waltham, MA) for in vitro assays.

fMET-mediated release of calprotectin from neutrophils

Neutrophils, 1–5 × 106 in 200 μl, from healthy individuals were incubated with fMLP (10 nM) at 37°C for 60 min. As a negative control, neutrophils were incubated with RPMI medium alone. The cells were pelleted by centrifugation and the supernatant was analyzed for calprotectin by ELISA as described above.

Reactive Oxygen Species (ROS)

Neutrophils, at a concentration of 3 x 105 cells/well, were incubated with the selective FPR1 inhibitor, cyclosporine H (CsH at 10 μΜ), the mitochondrial ROS scavenger, MitoTempo (10 μM), or the NADPH oxidase inhibitor, DPI (25 μM) for 30 min before addition of stimuli, such as R848 (2.5 μg/ml), formyl-methionine-leucyl-phenylalanine (fMLP) (5 μM) or plasma samples from vasculitis patients (n=14) and healthy controls (n=10) (1:50 dilution) for an additional 60 min. Approximately 80–95% of neutrophils were viable after neutrophil stimulation with plasma samples. To detect ROS generation, DHR 123 (0.5 μM) was added during the last 30 min of incubation, and analysis of ROS was performed by flow cytometry. Data were analyzed by FlowJo (Tree Star Inc, Ashland, OR), and the results were presented as the mean fluorescent intensity (MFI) of ROS.

Statistics

For samples with a non-Gaussian distribution, non-parametric tests, Mann-Whitney U test, Wilcoxon signed-rank test, and Spearman’s correlation were used as applicable. The 95th percentile of healthy controls was used to define the cut-off value for high levels of biomarkers. All analyses were considered statistically significant at p < 0.05.

Results

Demographic characteristics of the study population

The median age (range) of patients in remission at the time of diagnosis was 47 years of age (10–80) for the GPA cohort, whereas for the MPA cohort it was 59 years of age (17–82). With regards to LVV, the median age (range) of patients in remission was 30 (12–58) and 69 (54–90) years for the TAK and GCA cohorts, respectively. Sixty-four out of 123 (52%) patients with GPA, 31/61 (51%) with MPA, 53/58 (91%) with TAK, and 49/68 (72%) with GCA were female (Tables 1 and 2).

Neutrophil activation in patients with vasculitis

As depicted in Fig. 1A, levels of calprotectin were elevated in patients in remission with MPA (p<0.0001), GPA (p<0.0001), GCA (p<0.0001), and TAK (p=0.0004), as compared to healthy individuals, with 20–32% of the patients having highly elevated levels of calprotectin, as determined by the 95th percentile of healthy individuals. Comparing the vasculitis groups, no statistically significant difference could be seen with regards to calprotectin levels, suggesting neutrophil activation occurring at similar levels in both small and large-vessel vasculitis. In all, neutrophil activation is uniformly observed in patients with both large and small-vessel vasculitis.

Fig. 1
figure 1

Levels of neutrophil activation marker calprotectin in patients with AAV and LVV. Plasma levels of A calprotectin were measured by ELISA in healthy controls (HC), and patients with microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), giant cell arteritis (GCA), and Takayasu’s arteritis (TAK) in remission. Plasma levels of B calprotectin were related to disease activity in patients in remission (rem) and matching patients with active disease (active) as assessed by physician global assessment (PGA) in MPA, GPA, GCA, and TAK. Comparison of plasma levels of C calprotectin, among patients with GCA in the presence or absence of overlapping diagnosis of polymyalgia rheumatica (PMR): (PMR+, and PMR−, respectively). Statistical analyses were done using Mann-Whitney U test (A ,C), and Wilcoxon signed-rank test (B) with *p < 0.05, **p < 0.01, and ***p < 0.001. Unless otherwise indicated, all analyses are compared to healthy controls. Each circle represents an individual sample, with the bar representing the median of the group. The dotted line represents the 95th percentile of the HC

Full size image

Neutrophil activation is not associated with disease activity

No differences were seen in plasma levels of calprotectin between patients in remission and flare for any of the vasculitis groups investigated (Fig. 1B). Though not related to disease activity, levels of calprotectin correlated with systemic inflammation, including CRP (r=0.20, p=0.001) and ESR (r=0.24, p=0.0001).

We also assessed the correlation between serum creatinine (as a marker of kidney involvement) and calprotectin. Interestingly, levels of calprotectin correlated with creatinine in ANCA-associated vasculitis (MPA: r=0.35, p=0.01; GPA: r=0.41, p=0.001), but not in large-vessel vasculitis (GCA: r=0.01, p=0.92; TAK: r=−0.12, p=0.42).

Patients with overlapping GCA/PMR disease had significantly lower levels of calprotectin (p=0.04), as compared to patients with GCA without the diagnosis of PMR (Fig. 1C). In all, neutrophil activation markers were not associated with disease activity, but rather specific clinical features, such as kidney involvement in patients with AAV, and absence of PMR in patients with GCA.

Levels of circulating N-formyl methionine peptides in patients with vasculitis

As depicted in Fig. 2A, levels of fMET were elevated in all vasculitis groups (MPA, p=0.0001; GPA, p<0.0001; GCA, p<0.0001; and TAK, p<0.0001) as compared to healthy individuals, with 22–33% of the patients having highly elevated levels of fMET. Within the different vasculitis groups, fMET levels were higher in GPA as compared to MPA (p=0.04).

Fig. 2
figure 2

Levels of N formyl methionine peptides (fMET) in patients with AAV and LVV. Levels of A fMET were analyzed by ELISA in HC, and patients with MPA, GPA, GCA, and TAK in remission. Plasma levels of fMET (B) were related to disease activity in patients in remission (rem) and matching patients with active disease (active) as assessed by PGA in MPA, GPA, GCA, and TAK. Plasma levels of fMET correlated with CRP (C) and ESR (D). Statistical analyses were done using Mann-Whitney U test and Wilcoxon signed-rank test, with *p < 0.05, **p < 0.01, and ***p < 0.001. Each circle represents an individual sample, with the bar representing the median of the group. The dotted line represents the 95th percentile of the HC

Full size image

We also stratified patients based on positivity for either anti-PR3 or anti-MPO antibodies in GPA and MPA. We found that the presence of anti-PR3 antibodies in GPA, or anti-MPO antibodies in MPA, was not associated with elevated levels of fMET (p=0.76, and p=0.95, respectively) as compared to corresponding patients without these autoantibodies.

Further, in GPA, but not in the other vasculitides, levels of fMET were associated with active disease (p=0.02, Fig. 2B). Similarly to calprotectin, levels of fMET were correlated with CRP (r=0.82, p<0.0001), and ESR (r=0.35, p<0.0001) (Fig. 2C and D, respectively).

Neutrophil activation is partially mediated through fMET/FPR1 signaling in AAV and LVV

We then investigated whether levels of fMET were associated with markers of neutrophil activation in patients with vasculitis. Levels of fMET correlated with the neutrophil activation marker calprotectin (r=0.19, p=0.001), and patients with high fMET levels, had markedly elevated levels of calprotectin (p=0.002, Fig. 3A). Furthermore, in vitro activation of neutrophils from healthy donors with fMLP, a commonly used N-formyl methionine peptide, resulted in neutrophil activation and subsequent release of calprotectin (Fig. 3B), demonstrating that fMET directly could result in calprotectin release.

Fig. 3
figure 3

fMET-mediated release of calprotectin. Comparison of plasma levels of A calprotectin in patients with either high or low levels of fMET, as determined by the 95th percentile of HC. Neutrophils were activated by fMLP in vitro (B) and assessed for calprotectin release by ELISA. Statistical analyses were done using Mann-Whitney U test (A) and Wilcoxon signed-rank test (B), with *p < 0.05 and **p < 0.01. Each circle represents an individual sample, with the bar representing the median of the group

Full size image

To determine whether the circulating level of fMET had the capacity to induce de novo neutrophil activation in patients with vasculitis, neutrophils from healthy individual were incubated with healthy control (HC) and patient plasma and assessed for neutrophil activation as determined by ROS induction. A high proportion of plasma samples (7/14, 50%) from patients with AAV and LVV induced substantial ROS production (Fig. 4A).

Fig. 4
figure 4

fMET activates neutrophils in an FPR1-dependent manner. Neutrophils from a healthy donor were incubated with A plasma from healthy individuals (HC) or patients with vasculitis (Vasc) or B medium and fMLP in presence or absence of Cyclosporine H (CsH) and analyzed for ROS induction using flow cytometry. C Neutrophils were pre-incubated with inhibitors scavenging mitochondrial ROS (MitoTEMPO) and inhibiting NADPH oxidase (DPI) and analyzed for capacity to induce ROS production upon stimulation with media, TLR8 agonist R848, fMLP, and/or plasma from patients with vasculitis (n=10). Statistical analyses were done using Wilcoxon signed-rank test with * p < 0.05 and **p < 0.01. Each circle represents an individual sample, with the bar representing the median of the group

Full size image

Plasma samples potentially contain several neutrophil agonists, including inflammatory cytokines, immune complexes, and not least fMET. To determine whether plasma-mediated neutrophil activation was dependent on fMET in vasculitis, neutrophils were pre-treated with cyclosporine H. Blocking FPR1 with cyclosporine H reduced the capacity for plasma to induce neutrophil activation and ROS production in both HC and plasma from patients with vasculitis (p<0.01, Fig. 4A). As a control, CsH was shown to block fMLP-mediated neutrophil activation (p<0.05), but not that of medium control (Fig. 4B).

To further discriminate the origin of ROS production, neutrophils were pre-treated with mitoTEMPO and DPI, targeting either mitochondrial ROS or NADPH oxidase, respectively. Blocking NADPH oxidase, using DPI, completely abolished the capacity of TLR8 ligand R848, fMLP, or plasma from patients with vasculitis to induce ROS formation in neutrophils, whereas mitochondrial ROS was dispensable (Fig. 4C). Thus, our findings suggest that plasma from patients with vasculitis induces ROS through an FPR1- and NADPH oxidase-dependent manner.

Discussion

Mitochondria, due to their prokaryotic origin, contain several immunogenic molecules, including ATP, succinate, cardiolipin, fMET, mitochondrial DNA (mtDNA), and TFAM which, when misplaced from cells such as neutrophils, platelets, or damaged cells into the extracellular space, acquire the immunogenic capacity to drive autoimmune and inflammatory responses [30]. Although the presence of anti-cardiolipin antibodies has been reported in patients with AAV and LVV [31,32,33], implicating the presence of extracellular mitochondria exposing these immunogenic phospholipids, nothing is known about the presence and the role of other mitochondrial-derived damage-associated molecular patterns (DAMPs), including fMET, in systemic vasculitides.

In the current study, using samples from a well-characterized cohort collected in a protocolized fashion and at several different expert centers, we made the novel observation of fMET seeming to propagate neutrophil activation in both AAV and LVV in a FPR1-dependent manner, the main receptor for fMET [34]. Our findings suggest a central role of mitochondrial components in the pathogenesis of systemic vasculitides through immune activation of neutrophils that produce ROS predominantly from NADPH oxidase, and fMET-mediated signaling as a potential pharmacological target of these rare diseases. Of note, we recently described inhibition of fMET/FPR1 signaling with the selective FPR1 inhibitor cyclosporine H also in patients with RA, suggesting fMET-mediated neutrophil activation possibly being a central process in several autoimmune inflammatory conditions [26].

Consistent with elevated levels of fMET, we made the novel finding that patients with LVV, similarly to AAV, had marked neutrophil activation in peripheral blood, as evident by high levels of calprotectin. Our observation that fMLP can result in release of calprotectin from neutrophils aligns with previous studies that suggested a G protein-coupled pathway as a proposed mechanism [35]. The lack of association with disease activity is in contrast to some prior studies that showed a significant association between serum levels of calprotectin and disease activity in patients with AAV [36] and TAK [37]. However, in another study, serum calprotectin levels did not correlate with disease activity in TAK and GCA and failed to outperform traditional biomarkers such as ESR and CRP in reflecting disease activity in GCA [38].

It must be noted though that previous studies assessed levels of calprotectin in serum [36, 39], and not in plasma as done in the current study, which is an important distinction. We [5, 40], and others [41], have demonstrated that the process of coagulation induces the release of calprotectin. Thus, serum levels do not represent physiological levels of calprotectin, but artificial levels induced upon coagulation. Even so, levels of the neutrophil activation marker calprotectin correlated, though weakly, with markers of systemic inflammation, CRP and ESR, in contrast to prior work on serum levels of calprotectin in GCA [42] and AAV [43], further highlighting the necessity of assessing coagulation-sensitive biomarkers in plasma for consistent, and physiologically relevant, interpretations.

Although levels of neutrophil biomarkers could not distinguish the active disease from inactive disease, calprotectin may be useful as an organ-specific disease damage biomarker in patients with AAV, as it correlated with worsening kidney function in our study. Indeed, in another study, serum calprotectin was suggested as a potential renal prognosis biomarker in AAV [43]. Similar findings have also been seen in lupus nephritis [6, 44]. We also demonstrated that levels of fMET were associated with active disease in GPA. The elevated levels of fMET could be related to dysregulation of cell death pathways, as previous studies have shown that neutrophils derived from patients with GPA have dysregulation in proteinase 3-associated proteins that are associated with apoptosis such as annexin-A1 [45].

Importantly, levels of fMET, and calprotectin, were elevated in some patients with AAV and LVV in clinical remission, suggesting that these levels may indicate subclinical disease activity and smoldering vessel inflammation in systemic vasculitides. Similarly, previous studies showed elevated serum levels of calprotectin in patients in clinical remission with AAV [36], and RA [5] compared to healthy controls. Notably, calprotectin levels remained elevated in patients with GCA that were in treatment-free remission, qualifying it as a candidate marker for vascular inflammation monitoring [41]. Overall, our observations imply ongoing neutrophil activation and silent tissue inflammation in patients that are considered to have an inactive disease. Further studies are needed to determine underlying factors mediating neutrophil activation in otherwise quiescent disease.

Limitations of our study include the great heterogeneity and variability of our patient population, including the use of a variety of therapeutic agents that may have dampened the inflammatory response. Thus, prospective studies are needed to investigate whether immune-suppressive treatment, similar to what has been reported in lupus nephritis [44], can reduce levels of neutrophil activation markers. Another important consideration is that FPR1 is expressed not only by neutrophils but also by other cells that play a significant role in the pathogenesis of vasculitides such as platelets, monocytes, and macrophages, implying their potential activation by mitochondrial DAMPs in the circulation. The source of fMET could not be established in the current study, with fMET being derived from either mitochondria or bacteria. Indeed, one of the most abundant bacteria in the nasal microbiome of patients with GPA is Staphylococcus aureus (S. aureus) that could be an instigator of immune responses [46]. Bacterial formylated peptides from S. aureus are able to induce potent neutrophil chemotaxis in mice [47]. In another study, formylated peptides that were produced by wild-type strain of S. aureus were capable of inducing S. aureus septic arthritis [48] and a bacterial plasmid-encoded peptide from S. aureus was sufficient of causing MPO-ANCA glomerulonephritis in mice [49], illustrating the potency also of bacterial-derived fMET in causing disease. Further studies are warranted to elucidate the origin of fMET.

Conclusions

Neutrophil activation is prominent in patients with both AAV and LVV. Neutrophil activating factors such as fMET peptides are markedly increased in plasma from vasculitis and enhance inflammation through FPR1-mediated neutrophil activation. Upon validation with animal studies, fMET/FPR1-mediated signaling may be a novel therapeutic target in systemic vasculitides to limit neutrophil-mediated inflammation and tissue damage.

Availability of data and materials

All data relevant to this study are included in the article.

References

  1. Nauseef WM, Borregaard N. Neutrophils at work. Nat Immunol. 2014;15(7):602–11.

    Article  CAS  PubMed  Google Scholar 

  2. Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol. 2014;9:181–218.

    Article  CAS  PubMed  Google Scholar 

  3. Sorensen OE, Borregaard N. Neutrophil extracellular traps - the dark side of neutrophils. J Clin Invest. 2016;126(5):1612–20.

    Article  PubMed  PubMed Central  Google Scholar 

  4. de Bont CM, Eerden N, Boelens WC, et al. Neutrophil proteases degrade autoepitopes of NET-associated proteins. Clin Exp Immunol. 2020;199(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  5. Bach M, Moon J, Moore R, et al. A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020;72(1):47–56.

    Article  CAS  PubMed  Google Scholar 

  6. Moore S, Juo HH, Nielsen CT, et al. Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus. J Rheumatol. 2020;47(11):1652–60.

    Article  CAS  PubMed  Google Scholar 

  7. Duvvuri B, Pachman LM, Morgan G, et al. Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. Arthritis Rheumatol. 2020;72(2):348–58.

    Article  CAS  PubMed  Google Scholar 

  8. Soderberg D, Segelmark M. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. Front Immunol. 2016;7:256.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71.

    Article  PubMed  Google Scholar 

  10. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10(8):463–73.

    Article  CAS  PubMed  Google Scholar 

  11. Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol. 1990;81(2):311–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2012;14(3):R140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Porges AJ, Redecha PB, Kimberly WT, et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol. 1994;153(3):1271–80.

    CAS  PubMed  Google Scholar 

  14. Grayson PC, Tomasson G, Cuthbertson D, et al. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol. 2012;39(2):303–9.

    Article  PubMed  Google Scholar 

  15. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore). 2009;88(4):221–6.

    Article  Google Scholar 

  16. Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Banoth B, Cassel SL. Mitochondria in innate immune signaling. Transl Res. 2018;202:52–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med. 1982;155(1):264–75.

    Article  CAS  PubMed  Google Scholar 

  20. Dorward DA, Lucas CD, Chapman GB, et al. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. Am J Pathol. 2015;185(5):1172–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. 2002;23(11):541–8.

    Article  CAS  PubMed  Google Scholar 

  22. Thieblemont N, Wright HL, Edwards SW, et al. Human neutrophils in auto-immunity. Semin Immunol. 2016;28(2):159–73.

    Article  CAS  PubMed  Google Scholar 

  23. McDonald B, Pittman K, Menezes GB, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science. 2010;330(6002):362–6.

    Article  CAS  PubMed  Google Scholar 

  24. Nast CC, LeDuc LE. Chemotactic peptides. Mechanisms, functions, and possible role in inflammatory bowel disease. Dig Dis Sci. 1988;33(3 Suppl):50S–7S.

    Article  CAS  PubMed  Google Scholar 

  25. Anton PA, Targan SR, Shanahan F. Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology. 1989;97(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  26. Duvvuri B, Baddour AA, Deane KD, et al. Mitochondrial N-formyl methionine peptides associate with disease activity as well as contribute to neutrophil activation in patients with rheumatoid arthritis. J Autoimmun. 2021;119:102630.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mahr AD, Neogi T, Lavalley MP, Davis JC, et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener’s granulomatosis. Arthritis Rheum. 2008;59(6):884–91.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;27(5):178.

    Google Scholar 

  29. Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184(6):3284–97.

    Article  CAS  PubMed  Google Scholar 

  30. Rodriguez-Nuevo A, Zorzano A. The sensing of mitochondrial DAMPs by non-immune cells. Cell Stress. 2019;3(6):195–207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Savige JA, Chang L, Wilson D, et al. Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rheumatol Int. 1996;16(3):109–14.

    Article  CAS  PubMed  Google Scholar 

  32. Manna R, Latteri M, Cristiano G, et al. Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol. 1998;37(2):208–10.

    Article  CAS  PubMed  Google Scholar 

  33. Sebastian JK, Voetsch B, Stone JH, et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol. 2007;34(12):2446–50.

    PubMed  Google Scholar 

  34. Gabl M, Sundqvist M, Holdfeldt A, et al. Mitocryptides from human mitochondrial DNA-encoded proteins activate neutrophil formyl peptide receptors: receptor preference and signaling properties. J Immunol. 2018;200(9):3269–82.

    Article  CAS  PubMed  Google Scholar 

  35. Hetland G, Talgo GJ, Fagerhol MK. Chemotaxins C5a and fMLP induce release of calprotectin (leucocyte L1 protein) from polymorphonuclear cells in vitro. Mol Pathol. 1998;51(3):143–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Pepper RJ, Hamour S, Chavele KM, et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 2013;83(6):1150–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Goel R, Nair A, Kabeerdoss J, et al. Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study. Rheumatol Int. 2018;38(4):623–30.

    Article  CAS  PubMed  Google Scholar 

  38. Tombetti E, Hysa E, Mason JC, et al. Blood biomarkers for monitoring and prognosis of large vessel vasculitides. Curr Rheumatol Rep. 2021;23(3):17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Pepper RJ, Draibe JB, Caplin B, et al. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(1):185–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lood C, Tyden H, Gullstrand B, et al. Platelet-Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016;68(8):1970–80.

    Article  CAS  PubMed  Google Scholar 

  41. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113(19):2278–84.

    Article  CAS  PubMed  Google Scholar 

  42. van Sleen Y, Sandovici M, Abdulahad WH, et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford). 2019;58(8):1383–92.

    Article  CAS  Google Scholar 

  43. Martinez Valenzuela L, Draibe J, Quero Ramos M, et al. Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS One. 2018;13(10):e0205982.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Tyden H, Lood C, Gullstrand B, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(11):2048–55.

    Article  CAS  Google Scholar 

  45. Everts-Graber J, Martin KR, Thieblemont N, et al. Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance. Kidney Int. 2019;96(2):397–408.

    Article  CAS  PubMed  Google Scholar 

  46. Rhee RL, Lu J, Bittinger K, et al. Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2021;73(9):1703–12.

    Article  CAS  PubMed  Google Scholar 

  47. Southgate EL, He RL, Gao JL, et al. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol. 2008;181(2):1429–37.

    Article  CAS  PubMed  Google Scholar 

  48. Gjertsson I, Jonsson IM, Peschel A, et al. Formylated peptides are important virulence factors in Staphylococcus aureus arthritis in mice. J Infect Dis. 2012;205(2):305–11.

    Article  CAS  PubMed  Google Scholar 

  49. Ooi JDJJ, Eggenhuizen PJ, Chua LL, et al. A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic auto-immunity. Nat Commun. 2019;10(1):3392.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

DM is supported by the NIH training grant, award #5T32HL007028-44, and Pfizer US Pharmaceuticals Group grant (sponsor award number 53857367). PG is funded by NIAMS intramural program. TM is supported by NIH grants R21AR075134, R01AR074939, and R21AR077266. CL is supported by NIH grants 1R21EY029391 and R21AR075129.

The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC has received funding from NCATS, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319), the National Center for Research Resources (U54 RR019497), and GlaxoSmithKline.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, University of Washington, 750 Republican Street, Seattle, WA, 98109, USA

    Despina Michailidou, Bhargavi Duvvuri, Runa Kuley, Tomas Mustelin & Christian Lood

  2. Health Informatics Institute, University of South Florida, South Florida, Tampa, FL, USA

    David Cuthbertson

  3. Systemic Autoimmunity Branch, National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, USA

    Peter C. Grayson

  4. Division of Rheumatology, Mc Master University, Hamilton, Ontario, Canada

    Nader A. Khalidi

  5. Division of Rheumatology, University of Utah, Salt Lake City, UT, USA

    Curry L. Koening

  6. Division of Rheumatology, Cleveland Clinic, Cleveland, OH, USA

    Carol A. Langford

  7. Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA

    Carol A. McAlear, Antoine G. Sreih & Peter A. Merkel

  8. Division of Rheumatology and Clinical Immunology, University of Colorado, Denver, CO, USA

    Larry W. Moreland

  9. Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada

    Christian Pagnoux

  10. Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA

    Philip Seo

  11. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA

    Ulrich Specks

  12. Division of Rheumatology, Mayo Clinic, Rochester, MN, USA

    Kenneth J. Warrington

  13. Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, USA

    Paul A. Monach

Authors
  1. Despina Michailidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhargavi Duvvuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Runa Kuley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Cuthbertson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter C. Grayson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nader A. Khalidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Curry L. Koening
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carol A. Langford
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carol A. McAlear
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Larry W. Moreland
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Christian Pagnoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Philip Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ulrich Specks
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Antoine G. Sreih
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kenneth J. Warrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Tomas Mustelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Paul A. Monach
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Peter A. Merkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Christian Lood
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

D.M., B.D., R.K., T.M., and C.L. contributed to the conception and design of this study. D.M., B.D., R.K., and C.L. participated in experimental data collection and data analysis. D.K., P.C.G., N.A.K., C.L.K., C.A.L., C.A.M., L.W.M., C.P., P.S., U.S., A.G.S., K.J.W., P.A.M., and P.A.M. contributed with patient samples and clinical data. All authors contributed to data interpretation, critically reviewed and revised the manuscript, and approved the final submission.

Corresponding author

Correspondence to Christian Lood.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the regional ethics board at the University of Washington, Seattle, WA, (#3100).

Consent for publication

Informed written consent was obtained from all participants in accordance with the Helsinki Declaration.

Competing interests

Dr. Michailidou received Advisory Board fees from ChemoCentryx. Dr. Khalidi received clinical trial support from BMS, Sanofi, and Abbvie; travel support from Astra Zeneca; and an Advisory Board fee from Roche. Dr. Koening served on the advisory board for Chemocentryx and Genentech. Dr. Specks reports receiving funds for the following activities: Consulting: AstraZeneca, ChemoCentryx. Research Support: AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Genentech/Roche, InflaRx. Dr. Sreih works at Bristol-Myers Squibb and owns Astra Zeneca and Alexion Stocks. Dr. Warrington received clinical trial support from Eli Lilly and Kiniksa. Dr. Monach received consulting fees from Kiniksa, Celgene/BMC, and ChemoCentryx. Dr. Merkel reports receiving funds for the following activities: Consulting and Research Support: AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Takeda. Consulting only: CSL Behring, Dynacure, EMDSerono, Janssen, Kiniksa, Kyverna, Magenta, MiroBio, Neutrolis, Novartis, Pfizer, Sparrow, Talaris. Royalties: UpToDate. Dr. Mustelin received consulting fees from Cugene, Kiniksa, Miro Bio, and QiLu Pharmaceuticals; has an ownership share in Amdax; and has received research funding from Gilead Sciences. Dr. Lood received research funding from Exagen Inc, Pfizer, Gilead Sciences, and Eli Lilly.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Michailidou, D., Duvvuri, B., Kuley, R. et al. Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Res Ther 24, 160 (2022). https://doi.org/10.1186/s13075-022-02849-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13075-022-02849-z

Keywords

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us